# SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection

> **NCT07096882** · PHASE1 · RECRUITING · sponsor: **Cytocraft Biopharmaceutical Co., Ltd.** · enrollment: 22 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** SDT-M001 injection

## Key facts

- **NCT ID:** NCT07096882
- **Lead sponsor:** Cytocraft Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-26
- **Primary completion:** 2027-06-26
- **Final completion:** 2029-06-26
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07096882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07096882, "SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07096882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*